AstraZeneca Names New CFO Amidst Falling Sales And Profits

AstraZeneca plc (NYSE:AZN) (LON:AZN) named a new chief financial officer amidst reporting a sharp fall in its third-quarter sales and profits. Drug maker AstraZeneca plc (NYSE:AZN) (LON:AZN) reported earnings per share of $1.21, falling short of analysts’ estimates of $1.27. Marc Dunoyer to replace Simon Lowth Simon Lowth, AstraZeneca’s former CFO, announced his departure in July to take up the same position at BG Group plc. Lowth held the position of CFO of the Anglo-Swedish pharmaceuticals group since 2007. He served as interim CEO from June to October last year, when Soriot was recruited from rival Roche group. Previous CEO David Brennan…